Husam Alqaisi

A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

Stéphanie Lheureux, Husam Alqaisi, David E. Cohn et al. · Journal of Clinical Oncology · 2022 · 22 citations

Medicine, Oncology, Pharmacology +17

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)

Husam Alqaisi, David E. Cohn, Jing-Yi Chern et al. · Clinical Cancer Research · 2025 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

Esmail Mutahar Al-Ezzi, Husam Alqaisi, Marco Iafolla et al. · Cancer Medicine · 2021 · 10 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial.

Ana Veneziani, Stéphanie Lheureux, Husam Alqaisi et al. · Journal of Clinical Oncology · 2022 · 10 citations

Medicine, Oncology, Pharmacology +17

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy

Husam Alqaisi, Carlos Stecca, Zachary Veitch et al. · Therapeutic Advances in Medical Oncology · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacology +12